GH Stock Overview
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
Guardant Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$35.09|
|52 Week High||US$133.82|
|52 Week Low||US$27.65|
|1 Month Change||-51.26%|
|3 Month Change||-51.52%|
|1 Year Change||-68.85%|
|3 Year Change||-55.17%|
|5 Year Change||n/a|
|Change since IPO||8.98%|
Recent News & Updates
Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Guardant Health: Leaping Growth With Epic
Amid a down market, Guardant shares are trading at a bargain to their estimated value. Meanwhile, Guardant continues to procure robust sales increases and narrowed its bottom line depreciation. The recent Epic deal for its diagnostics to reach over 250M patients is a transformative milestone to galvanize forward revenues.
|GH||US Healthcare||US Market|
Return vs Industry: GH underperformed the US Healthcare industry which returned 4% over the past year.
Return vs Market: GH underperformed the US Market which returned -10.4% over the past year.
|GH Average Weekly Movement||15.6%|
|Healthcare Industry Average Movement||10.1%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: GH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: GH's weekly volatility has increased from 10% to 16% over the past year.
About the Company
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.
Guardant Health Fundamentals Summary
|GH fundamental statistics|
Is GH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GH income statement (TTM)|
|Cost of Revenue||US$126.15m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.11|
|Net Profit Margin||-107.20%|
How did GH perform over the long term?See historical performance and comparison
Is Guardant Health undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GH's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: GH is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: GH is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GH is overvalued based on its PB Ratio (6.7x) compared to the US Healthcare industry average (2.5x).
How is Guardant Health forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GH's revenue (23.3% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: GH's revenue (23.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GH is forecast to be unprofitable in 3 years.
How has Guardant Health performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GH is currently unprofitable.
Growing Profit Margin: GH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GH is unprofitable, and losses have increased over the past 5 years at a rate of 49% per year.
Accelerating Growth: Unable to compare GH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (9.6%).
Return on Equity
High ROE: GH has a negative Return on Equity (-75.16%), as it is currently unprofitable.
How is Guardant Health's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: GH's short term assets ($1.1B) exceed its short term liabilities ($228.8M).
Long Term Liabilities: GH's short term assets ($1.1B) do not cover its long term liabilities ($1.4B).
Debt to Equity History and Analysis
Debt Level: GH's net debt to equity ratio (32.5%) is considered satisfactory.
Reducing Debt: GH's debt to equity ratio has increased from 9% to 213% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GH has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: GH has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 34.2% each year.
What is Guardant Health current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GH has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Helmy Eltoukhy (42 yo)
Dr. Helmy Eltoukhy, Ph D., has been the Chairman of the Board of Directors of Guardant Health, Inc. since August 05, 2021. He has been the Co-Chief Executive Officer at Guardant Health, Inc. since August 0...
CEO Compensation Analysis
Compensation vs Market: Helmy's total compensation ($USD13.67K) is below average for companies of similar size in the US market ($USD6.90M).
Compensation vs Earnings: Helmy's compensation has been consistent with company performance over the past year.
Experienced Management: GH's management team is considered experienced (2 years average tenure).
Experienced Board: GH's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Guardant Health, Inc.'s employee growth, exchange listings and data sources
- Name: Guardant Health, Inc.
- Ticker: GH
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$3.576b
- Shares outstanding: 101.92m
- Website: https://guardanthealth.com
Number of Employees
- Guardant Health, Inc.
- 505 Penobscot Drive
- Redwood City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.